

USSN: 10/091,258

Amdt. Dated: June 28, 2004

Reply to Office Action of February 26, 2004

Page 5 of 11

Amendments to the Claims:

This listing of claims will replace all prior versions and listings of claims in the application:

Listing of Claims:

1. (Currently amended) A method of treating or preventing intermittent claudication in a subject comprising the step of administering a therapeutically effective amount of ~~GLP-1 molecule~~ a molecule selected from the group consisting of a glucagon-like peptide-1 (GLP-1), a biologically active fragment, variant, analog, mimetic, agonist or derivative thereof, and an exendin.
2. (Currently amended) A method of treating or preventing skeletal muscle injury caused by ischemia and/or reperfusion in a subject comprising the step of administering a therapeutically effective amount of ~~GLP-1 molecule~~ a molecule selected from the group consisting of a GLP-1, a biologically active fragment, variant, analog, or derivative thereof, and an exendin.
3. (Currently amended) The method according to claim 1 or 2, wherein the GLP-1 molecule is selected from the group consisting of GLP-1(7-36)NH₂ (SEQ ID NO:4), GLP-[[4]] 1(7-37), exendin-3 and exendin-4.
4. (Currently amended) The method according to claim 1 or 2 wherein the GLP-1 molecule is selected from the group consisting of GLP-1(7-36)NH₂ (SEQ ID NO:4) and GLP-1(9-36)NH₂ (SEQ ID NO:6).
5. (Original) The method according to claim 1 or 2, wherein the subject is also administered free radical scavengers.
6. (Original) The method according to claim 5, wherein the free radical scavenger is selected from the group consisting of glutathione, melatonin, Vitamin E, and superoxide dismutase.

USSN: 10/091,258

Amdt. Dated: June 28, 2004

Reply to Office Action of February 26, 2004

Page 6 of 11

7. (Original) The method according to claim 1 or 2, wherein the subject is also administered glucose.
8. (Original) The method according to claim 7, wherein the subject is also administered potassium.
9. (Currently amended) The method according to claim 1 or 2, wherein the subject is suffering from Peripheral Vascular Disease (PVD) ~~PVD~~.
10. (Original) The method according to claim 1 or 2, wherein the subject is human.
11. (Currently amended) The method according the claim 1 or 2, wherein the ~~GLP-1~~ molecule is administered by an infusion pump or by subcutaneous injection of a slow release formulation of the molecule.